What does the National Comprehensive Cancer Network (NCCN) recommend against in the treatment of acute promyelocytic leukemia (APL)?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

The NCCN recommends that the following not be used in APL patients:

  • Leukapheresis, except in life-threatening cases with leukostasis that is unresponsive to other treatment

  • Myeloid growth factors

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!